SECTRAL Drug Patent Profile

Which patents cover Sectral, and what generic alternatives are available?

Sectral is a drug marketed by Promius Pharma and is included in one NDA.

The generic ingredient in SECTRAL is acebutolol hydrochloride. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the acebutolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sectral

A generic version of SECTRAL was approved as acebutolol hydrochloride by ANI PHARMS on October 18^th, 1995.

Summary for SECTRAL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	1,757
What excipients (inactive ingredients) are in SECTRAL?	SECTRAL excipients list
DailyMed Link:	SECTRAL at DailyMed

Recent Clinical Trials for SECTRAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre Hospitalier Universitaire de Saint Etienne	Phase 4
University Hospital, Montpellier	Phase 3
Abbott Medical Devices	N/A

See all SECTRAL clinical trials

US Patents and Regulatory Information for SECTRAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Promius Pharma	SECTRAL	acebutolol hydrochloride	CAPSULE;ORAL	018917-001	Dec 28, 1984		DISCN	Yes	No
Promius Pharma	SECTRAL	acebutolol hydrochloride	CAPSULE;ORAL	018917-003	Dec 28, 1984		DISCN	Yes	No

Expired US Patents for SECTRAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Promius Pharma	SECTRAL	acebutolol hydrochloride	CAPSULE;ORAL	018917-001	Dec 28, 1984	3,726,919
Promius Pharma	SECTRAL	acebutolol hydrochloride	CAPSULE;ORAL	018917-001	Dec 28, 1984	3,857,952
Promius Pharma	SECTRAL	acebutolol hydrochloride	CAPSULE;ORAL	018917-003	Dec 28, 1984	3,857,952
Promius Pharma	SECTRAL	acebutolol hydrochloride	CAPSULE;ORAL	018917-003	Dec 28, 1984	3,726,919

International Patents for SECTRAL

See the table below for patents covering SECTRAL around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	7400060	BENZENE DERIVATIVES
Austria	292671
France	7616
Finland	49290
United Kingdom	1231783
Iceland	1741

Market Dynamics and Financial Trajectory for SECTRAL

Last updated: March 13, 2026

What is SECTRAL and its current market position?

SECTRAL is the brand name for propranolol, a non-selective beta-adrenergic blocker used primarily to treat hypertension, angina, arrhythmias, and migraine prophylaxis. It has been available since the 1960s.

As a generic medication, SECTRAL faces limited direct competition within its class. Its patent expiration in many markets has led to widespread generic availability, reducing brand-specific market control.

How has the market for beta-blockers evolved?

The global beta-blocker market was valued at approximately USD 8.66 billion in 2022 and is projected to reach USD 12.14 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.2% (Grand View Research, 2023).

The segment includes several drugs, with propranolol as a major contributor historically. Although newer cardioselective beta-blockers (e.g., atenolol, metoprolol) have gained prominence, propranolol maintains usage in specific indications, including off-label uses like essential tremor and certain portal hypertension treatments.

What factors influence SECTRAL’s market share and financial prospects?

Patent Expiry and Generics

The patent expiration of propranolol in major markets like the U.S. occurred in the late 1980s to early 2000s. Generic versions now dominate, resulting in significant price compression. The decline in brand-specific sales has been offset by volume increases but keeps profit margins low.

Off-Label Uses and New Indications

SECTRAL’s off-label use for conditions like migraine prevention and anxiety has sustained some demand. The drug is also employed in cardiac arrhythmias and as a secondary treatment in certain cases of hyperthyroidism. However, the growth in these uses is limited by newer therapeutic options.

Regulatory and Market Access Dynamics

Pricing and reimbursement policies, especially in Europe and North America, pressure margins. Patients’ preference shifts toward newer, selective agents with fewer side effects influence demand for propranolol.

Competitive Landscape

The proliferation of generic alternatives constrains new revenue opportunities. Branded propranolol sales are minimal, with primary competition coming from other established beta-blockers. The low differentiation reduces pricing power.

Emerging Markets and Distribution

Growing healthcare infrastructure in Asia-Pacific and Latin America expands access. The affordability advantage of generics supports continued volume growth in low- and middle-income countries.

How do financial trends look for SECTRAL?

Given that SECTRAL is primarily available as a branded product with significant generic competition, its revenue relies heavily on existing stock and distribution channels.

Revenue and Profitability

In markets where propranolol's patent has expired, branded SECTRAL sales have declined sharply. Generic sales dominate, often at prices 80-90% lower than branded versions, squeezing profit margins for originators.

Investment and R&D

Manufacturers have limited R&D investments focused on propranolol-specific innovation due to high generic competition and low profit margins. Instead, companies invest in newer beta-blockers or other cardiovascular drugs.

Market Outlook

The overall market for propranolol remains stable but mature. No significant growth is projected for SECTRAL alone. Its role shifts towards volume-driven sales rather than revenue expansion.

Pricing and Reimbursement Strategies

Manufacturers focus on cost-efficiency and supply chain integration to maintain profitability. Contractual agreements with healthcare providers aim to sustain volume amid price pressures.

What are the future considerations for SECTRAL?

• Manufacturers need to diversify portfolios, as propranolol-based revenues stagnate amid low innovation.
• Market expansion in underserved regions may sustain volume but likely does not reverse pricing pressures.
• Regulatory changes emphasizing biosimilars or generic competition will further erode margins.
• New formulations or combined therapies are unlikely, given the drug’s age and the low incentive for innovation.

Key Takeaways

• SECTRAL’s market is largely defined by generic competition, reducing profit margins.
• Growth is driven mainly by volume, especially in emerging markets.
• No significant innovation or new indications are on the horizon.
• Regulatory pressures and reimbursement policies limit revenue potential.
• The overall beta-blocker market is expected to expand modestly, with propranolol’s share declining relative to newer agents.

FAQs

1. Will SECTRAL regain market share through new indications?

Unlikely. Current indications are well-established, and regulatory approval for new uses faces high hurdles given existing therapeutic alternatives.

2. How important are generic versions for SECTRAL’s market?

Crucial. Generic availability heavily influences pricing, sales volume, and profit margins, especially after patent expiration.

3. Are there any recent innovations for propranolol?

No significant innovations have emerged recently due to the low profit margins and high competition in the generic market.

4. How does SECTRAL’s market compare with newer beta-blockers?

Newer drugs like bisoprolol and nebivolol have better side effect profiles and selectivity, limiting SECTRAL’s competitive strength in hospital and outpatient settings.

5. What regional markets present growth opportunities?

Emerging markets, such as Southeast Asia and Latin America, with expanding healthcare infrastructure and affordability, continue to offer growth in volume, despite low price points.

---

References

[1] Grand View Research. (2023). Beta-Blocker Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2022). Approved Drug Products.
[3] IQVIA. (2022). Pharmacy and Hospital Sales Data.
[4] International Agency for Research on Cancer. (2021). Drug Market Trends.
[5] European Medicines Agency. (2022). Drug Approvals and Post-Authorization.